Capricor Therapeutics CAPR Business Segments — Operating Income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Capricor Therapeutics's business segments — operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Capricor Therapeutics's business segments — operating income?
- Capricor Therapeutics (CAPR) reported business segments — operating income of -$36.77M in Q1 2026.
- How has Capricor Therapeutics's business segments — operating income changed year-over-year?
- Capricor Therapeutics's business segments — operating income decreased by 47.2% year-over-year, from -$24.98M to -$36.77M.
- What does business segments — operating income mean?
- This metric represents the profit or loss generated from the company's core business operations before accounting for interest, taxes, and non-operating items. It reflects the efficiency of the company's primary research, development, and commercialization activities. For a biotechnology firm, this highlights the burn rate associated with advancing clinical pipelines.